Jolanta Krucinska
Overview
Explore the profile of Jolanta Krucinska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
608
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozcan Tezgin D, Kurkcu S, Si D, Krucinska J, Mosley A, Mehta P, et al.
Biochem Pharmacol
. 2024 Nov;
230(Pt 3):116617.
PMID: 39528074
Cellular resistance can limit the effectiveness of antifolate drugs for the treatment of cancer and autoimmune diseases. We examined the biochemical and cellular effects of a propargyl linked, non-classical antifolate...
2.
Krucinska J, Lombardo M, Erlandsen H, Estrada A, Si D, Viswanathan K, et al.
Commun Biol
. 2022 May;
5(1):459.
PMID: 35562546
Two plasmid-encoded dihydrofolate reductase (DHFR) isoforms, DfrA1 and DfrA5, that give rise to high levels of resistance in Gram-negative bacteria were structurally and biochemically characterized to reveal the mechanism of...
3.
Krucinska J, Lombardo M, Erlandsen H, Hazeen A, Duay S, Pattis J, et al.
Sci Rep
. 2019 Nov;
9(1):17106.
PMID: 31745118
Many years ago, the natural secondary metabolite SF2312, produced by the actinomycete Micromonospora, was reported to display broad spectrum antibacterial properties against both Gram-positive and Gram-negative bacteria. Recent studies have...
4.
Reeve S, Si D, Krucinska J, Yan Y, Viswanathan K, Wang S, et al.
ACS Infect Dis
. 2019 Oct;
5(11):1896-1906.
PMID: 31565920
The spread of plasmid borne resistance enzymes in clinical isolates is rendering trimethoprim and iclaprim, both inhibitors of dihydrofolate reductase (DHFR), ineffective. Continued exploitation of these targets will require compounds...
5.
Hajian B, Scocchera E, Shoen C, Krucinska J, Viswanathan K, G-Dayanandan N, et al.
Cell Chem Biol
. 2019 Apr;
26(6):781-791.e6.
PMID: 30930162
The folate biosynthetic pathway offers many druggable targets that have yet to be exploited in tuberculosis therapy. Herein, we have identified a series of small molecules that interrupt Mycobacterium tuberculosis...
6.
Krucinska J, Falcone E, Erlandsen H, Hazeen A, Lombardo M, Estrada A, et al.
Biochemistry
. 2019 Feb;
58(9):1188-1197.
PMID: 30714720
Enolase is a glycolytic metalloenzyme involved in carbon metabolism. The advantage of targeting enolase lies in its essentiality in many biological processes such as cell wall formation and RNA turnover...
7.
Reeve S, Scocchera E, G-Dayanadan N, Keshipeddy S, Krucinska J, Hajian B, et al.
Cell Chem Biol
. 2016 Dec;
23(12):1458-1467.
PMID: 27939900
Antibiotic resistance is a rapidly evolving health concern that requires a sustained effort to understand mechanisms of resistance and to develop new agents that overcome those mechanisms. The dihydrofolate reductase...
8.
Hajian B, Scocchera E, Keshipeddy S, G-Dayanandan N, Shoen C, Krucinska J, et al.
PLoS One
. 2016 Sep;
11(8):e0161740.
PMID: 27580226
Mycobacterium tuberculosis continues to cause widespread, life-threatening disease. In the last decade, this threat has grown dramatically as multi- and extensively-drug resistant (MDR and XDR) bacteria have spread globally and...
9.
Can M, Krucinska J, Zoppellaro G, Andersen N, Wedekind J, Hersleth H, et al.
Chembiochem
. 2013 Aug;
14(14):1828-38.
PMID: 23908017
Nitrosomonas europaea cytochrome c-552 (Ne c-552) variants with the same His/Met axial ligand set but with different EPR spectra have been characterized structurally, to aid understanding of how molecular structure...
10.
Liberman J, Salim M, Krucinska J, Wedekind J
Nat Chem Biol
. 2013 Apr;
9(6):353-5.
PMID: 23584677
PreQ1 riboswitches regulate genes by binding the pyrrolopyrimidine intermediate preQ1 during the biosynthesis of the essential tRNA base queuosine. We report what is to our knowledge the first preQ1-II riboswitch...